• BioAdaptives swung to net income of US$ 150,090 in the quarter ended June 30, 2026, from a net loss of US$ 157,914.
• Revenue more than doubled to US$ 4,249 from a year earlier, while operating expenses fell 28.14% to US$ 201,416.
• Other income rose to US$ 347,266, reflecting a US$ 446,739 change in the fair value of derivative liabilities.
• Cash totaled US$ 29,221 at June 30, 2026, with a working-capital deficit of US$ 1.77 million.
• Business updates included May test marketing for MyndSystem, slow early marketing for Xcellara, and limited PawPa Regen sales via its website and Amazon.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAdaptives Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001393), on August 19, 2026, and is solely responsible for the information contained therein.